Market Access News | pharmaphorum

News

Alnylam gets NICE backing for porphyria therapy Givlaari

UK cost-effectiveness watchdog NICE is set to recommend NHS use of Alnylam's gene-silencing therapy Givlaari in England and Wales for the rare disease acute hepatic porphyria (AHP), after i

News

Biogen, Sage prep 2022 filing for depression drug zuranolone

The renaissance of Biogen and Sage Therapeutics antidepressant zuranolone continues, with the companies indicating they now plan to start a rolling submission for the drug early next year.<

News

Omeros seeks urgent FDA meeting after it rejects key drug

Shares in Omeros plummeted yesterday after the FDA rejected approval of its narsoplimab drug for a rare and life-threatening complication of haematopoietic stem cell transplants (HSCT), say

News

Doctor in the hand shows the scanning of the lung of the person.

NICE changes stance on Sanofi's Dupixent for severe asthma

18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug.

News

Califf re-joining FDA would be positive for industry; analys...

With rumours growing that that ex-FDA head Robert Califf looks set to receive President Joe Biden's nomination to be the next FDA commissioner, at least one analyst thinks the appointment w

News

Merck files pill for milder COVID, as AZ showcases its antib...

As expected, Merck & Co has moved ahead swiftly with an emergency use application for its oral antiviral molnupiravir, aiming to protect people with mild or moderate COVID-19 from devel

Alnylam gets NICE backing for porphyria therapy Givlaari

Biogen, Sage prep 2022 filing for depression drug zuranolone

Omeros seeks urgent FDA meeting after it rejects key drug

NICE changes stance on Sanofi's Dupixent for severe asthma

Califf re-joining FDA would be positive for industry; analys...

Merck files pill for milder COVID, as AZ showcases its antib...

Datroway joins Trodelvy for frontline TNBC in the EU

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks